Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 2, 2008, Pages 115-122

  Chianelli, Marco ^a,b   Parisella, M G ^c   Visalli, Natalia ^d   Mather, S J ^e   D'Alessandria, C ^c   Pozzilli, Paulo ^f,g   Signore, A ^b,c   Manfrini, Silvia ^h   Fioriti, Elvira ^h   Coppolino, Giusy ^h   Valente, Luciana ^h   Guglielmi, Chiara ^h   Anguissola, Giuseppina Beretta ^h   Costanza, Flavia ^h   Montemari, Anna Lisa ^h   Cipolloni, Laura ^h   Pantano, Angelo Lauria ^h   Picardi, Antonio ^h   Merola, Manon Khazrai ^h   Cavallo, M Gisella ^h   Matteoli, Maria C ^h   Patera, I Patrizia ^h   Cappa, Marco ^h   Crinò, Antonio ^h   Corbi, Stefania ^h   Spera, Sabrina ^h   Schiaffini, Riccardo ^h   Suraci, Concetta ^h   Cervoni, Marco ^h   MancaBitti, Maria L ^h   Bizzarri, Carla ^h   Pitocco, Dario ^h   Ghirlanda, Giovanni ^h   more..

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SANDRO PERTINI HOSPITAL   (Italy)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h NONE

Author keywords

99mTc IL2 scintigraphy; Activated lymphocytes; Interleukin 2; Nicotinamide; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NICOTINAMIDE; TECHNETIUM 99M;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; IMMUNOLOGICAL PARAMETERS; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; METABOLIC PARAMETERS; MULTICENTER STUDY; PANCREAS SCINTISCANNING; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; NIACINAMIDE; ORGANOTECHNETIUM COMPOUNDS; PANCREAS;

EID: 39649115219     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.767     Document Type: Article

References (41)

1. Gorus FK, The Belgian Diabetes Registry. Diabetes registries and early biological markers of Insulin-dependent diabetes mellitus. Diabetes Metab Res Rev 1997; 13: 247-274.
2. Eisenbarth GS. Type 1 diabetes: a chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1367.
3. De Fronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3: 510-547.
4. Pipeleers D, Ling Z. Pancreatic b-cells in insulin dependent diabetes. Diabetes Metab Res Rev 1992; 8: 209-227.
5. Imagawa A, Hanafusa T, Itoh N, et al. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 42: 574-578.
6. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long term complications in insulin dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
7. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 1982; 31: 749-753.
8. Pozzilli P, Browne P, Kolb H, The Nicotinamide Trialists. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. Diabetes Care 1996; 19: 1357-1363.
9. Kolb H, Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 1999; 22(Suppl. 2): B16-B20.
10. Sweet IR, Cook DL, Lernmark A, et al. Systematic screening of potential b-cell imaging agents. Biochem Biophys Res Commun 2004; 314: 976-983.
11. 99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. J Nucl Med Biol 1997; 24: 579-586.
12. Robb RJ, Munck A, Smith KA. T-cell growth factor receptors: quantitation, specificity and biological relevance. J Exp Med 1981; 154: 1455-1474.
13. Signore A, Chianelli M, Annovazzi A, et al. Imaging of active lymphocytic infiltration in coeliac disease with 123I-Interleukin-2 and its response to diet. Eur J Nucl Med 2000; 27: 18-24.
14. Signore A, Chianelli M, Annovazzi A, et al. 123I-Interleukin-2 scintigraphy for the in vivo assessment of intestinal mononuclear cell infiltration in Chron's disease. J Nucl Med 2000; 41: 242-249.
15. Signore A, Parman A, Pozzilli P, Andreani D, Beverely PCL. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-labelled interleukin-2: an early sign of type 1 diabetes. Lancet 1987; 2: 537-540.
16. Signore A, Chianelli M, Ferretti E, et al. New approach for in vivo detection of insulitis in type 1 diabetes: activated lymphocyte targeting with 123I labelled interleukin-2. Eur J Endocrinol 1994; 131: 431-437.
17. Visalli N, Cavallo MG, Signore A, et al., The IMDIAB Study Group, Roma, Italy. A multi-centre randomised trial of two different doses of nicotinamide in patients with recent onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev 1999; 15: 181-185.
18. Greenbaum CJ, Harrison LC, The Immunology of Diabetes Society. Perspectives in diabetes guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003; 52: 1058-1065.
19. Dean BM, Becker F, Mc Nally JM, et al. Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes. Diabetologia 1986; 29: 339-342.
20. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM. Prediction of IDDM in the general population. Strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701-1710.
21. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
22. Proujansky R, Carpenter AB. Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1991; 13: 277-284.
23. 99mTc-HIG in patients with type 1 diabetes. Eur J Nucl Med 1998; 25: 503-508.
24. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
25. Kaldany A, Hill T, Wentworth S, et al. Trapping of peripheral blood lyphocytes in the pancreas of patient with acute-onset insulin dependent diabetes mellitus. Diabetes 1982; 31: 463-466.
26. Gallina DL, Pelletier D, Doherty P, et al. 111Indium-labelled lymphocytes do not image or label the pancreas of BB/W rat. Diabetologia 1985; 28: 143-147.
27. Turvey SE, Swart E, Denis MC, et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest 2005; 115: 2454-2461.
28. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8 T-Cells to the pancreas in real time. Diabetes 2004; 53: 1459-1466.
29. Giordano C, Galluzzo A, Marco A. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res 1988; 8: 135-138.
30. Vialettes B, Schmitt N, Hirn M, et al. The soluble receptor of interleukin-2 is not a serum marker of the autoimmune activity in type 1 diabetes mellitus. Autoimmunity 1991; 11: 53-59.
31. Wagner R, Bonifacio E, Bingley PJ, Genovese S, Reinwein D, Bottazzo GF. Low interleukin-2 receptor levels in serum of patients with insulin dependent diabetes. Clin Invest 1994; 72: 494-498.
32. Rolandsson O, Stigbrand T, Riklundahlstrom K, Eary J, Greenbaum C. Accumulation of (125)iodine labeled interleukin-2 in the pancreas of NOD mice. J Autoimmun 2001; 17: 281-287.
33. 123I-Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity. J Pediatr Endocrinol Metab 1996; 9: 139-144.
34. 99mTc-labelling of interleukin-2 for in vivo targeting of immune mediated process. PhD thesis: London, 1996.
35. Kolb H. Benign vs destructive insulitis. Diabetes Metab Res Rev 1997; 13: 139-146.
36. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The deutsche nicotinamide intervention study. An attempt to prevent Type 1 diabetes. Diabetes 1998; 47: 980-984.
37. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995; 38: 848-852.
38. Lernmark A. Type 1 diabetes: does suppressing T cells increase insulin? N Eng J Med 2005; 352: 1644-1646.
39. Pozzilli P, Visalli N, Buzzetti R, et al. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. Metabolism 1998; 47: 1205-1210.
40. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 1996; 45: 1631-1634.
41. Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004; 89: 2222-2227.